Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: neuraxpharm Arzneimittel GmbH, Elisabeth-Selbert-Str. 23, 40764, Langenfeld, Germany
Ethosuximide neuraxpharm 50 mg/ml oral solution.
| Pharmaceutical Form |
|---|
|
Oral solution. Clear, colourless to slightly yellow solution. |
1 ml oral solution contains 50 mg ethosuximide.
Excipients with known effect: 1 ml oral solution contains 0.6 mg Methyl-4-hydroxybenzoate (E218).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Aethosuximide |
Ethosuximide is an anti-epileptic of the class of succinimides that apparently exerts multiple mechanisms of action. The activity of ethosuximide in absence type epilepsy seems to rely primarily on the inhibition of T-type calcium channels in the thalamus. |
| List of Excipients |
|---|
|
Methyl-4-hydroxybenzoate (E218) |
Brown glass bottle (glass type III) with screw cap (polypropylene/polyethylene).
Packs of 125 ml or 250 ml (2 × 125 ml) oral solution in a carton containing also a 10 ml graduated oral syringe, graduated in 0.5 ml steps and an adapter for the oral syringe.
Not all pack sizes may be marketed.
neuraxpharm Arzneimittel GmbH, Elisabeth-Selbert-Str. 23, 40764, Langenfeld, Germany
PL 48035/0024
21/06/2018
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
